How these IPOs fared 1 week later

This is how the latest shares listing on the ASX performed.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first week of a company being on the ASX boards can be very telling. The market doesn't get any new information until the next quarterly or half-year result, so we can get a sense of the market sentiment from how the share does in its first week.

Of course, how the market treats a share doesn't ultimately mean anything. But, it can be interesting nonetheless.

Here are how the latest ASX shares fared:

Constellation Resources Limited (ASX: CR1)

This company is a resource exploration business. It holds the Orpheus Project, which comprises five tenements covering approximately 552km² in a prospective portion of the Fraser Range province of Western Australia. The region could have nickel, copper and gold after a discovery in 2012.

It was looking to raise money at $0.20 per share and it's currently trading at $0.305, which shows a quick 52% return.

Tempus Resources Ltd (ASX: TMR)

Tempus is also a resource exploration business. It has a 90% interest in a business which is the registered holder of the Montejinni Project in the Northern Territory and the Claypan Dam Project in South Australia. Its focus will be looking for copper but it will also look for other resources.

It was also looking to start trading on 30 July 2018, but it appears to not have made it onto the boards. There is no new expected listing date according to the ASX.

Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)

It's a biopharmaceuticals business. It is developing peptide-based pharmaceutical products that target a number of neurological disorders that have high unmet medical needs. The current R&D program is focused on developing a treatment for stroke-related brain injury and dementia / Alzheimer's disease, and a diagnostic for early-stage Alzheimer's disease.

It was looking to raise money at $0.20 per share and it's now trading at $0.25 per share, showing a quick 25% gain since listing last week.

Foolish takeaway

If I had to invest in one share it would be Neuroscientific Biopharmaceuticals as I'm really not a fan of resource shares in general. However, they are all too speculative for me, so I'm personally going to invest in other things.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Capital Raising

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Capital Raising

DroneShield shares freeze on $75 million for AI and inventory

This defence tech stock is rattling the can for a chunk of cash.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Technology Shares

What's happening with the NextDC share price on Thursday?

NextDC is raising $1.32 billion to accelerate its data centre developments amid the rapid growth of AI.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Capital Raising

Up 102% in 2024, here's why this ASX All Ords stock is now frozen

Seize the day. This company is ready to cash in on its renewed image.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Materials Shares

Why is this ASX 300 battery materials stock crashing 20% today?

Its shares are now down by 67% since this time last year.

Read more »

A man with a heavy facial hair growth and a comical look on his face holds his hands in a 'time out' gesture.
Energy Shares

Up 90% in a year, why is this ASX 300 uranium stock suddenly halted?

Here's why this high-flying stock is out of action today.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Mergers & Acquisitions

Why are Metcash shares tumbling today?

This wholesaler has just received a $300 million cash injection.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Materials Shares

Why is the Arafura share price sinking 17% today?

It has been a tough session for this rare earths stock. But why?

Read more »

Two happy pharmacists standing together in a pharmacy.
Capital Raising

Own Sigma shares? Everything you need to know about the 'transformational' $8.8b merger with Chemist Warehouse

Here's what you need to know about this mega merger.

Read more »